Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study will not change the clinical treatment plan.
• Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck
• Subjects newly diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection.
• Subjects are to be staged clinically and radiographically node negative (cN0)
• Planned standard of care surgery with curative intent for squamous cell carcinoma
• Age \> 18 years
• Have acceptable hematologic status, coagulation status (11 to 13.5 seconds. international normalized ratio (INR) of 0.8 to 1.1), kidney function, and liver function including the following clinical results:
‣ Hemoglobin ≥ 9 gm/dL
⁃ White blood cell count ≥ 3000/mm3
⁃ Platelet count ≥ 100,000/mm3
⁃ Serum creatinine ≤ 1.5 times upper reference range
⁃ alanine transaminase (ALT) (SGPT) 7-56 units/liter, aspartate aminotransferase (AST) (SGOT) 5-40 units/liter.